Participated · Series B · Jul 2026

TwelveLabs develops foundational video models and an end-to-end video cognition platform that converts raw video into structured, searchable intelligence. Its Marengo 3.0 model provides advanced video embeddings and its Pegasus 1.5 model extracts structured scene boundaries, entities, and temporal segments; both models are distributed via TwelveLabs’ API and Amazon Bedrock. The company has begun moving beyond models into a full-stack agentic architecture that maintains persistent, compoundable memory of indexed video and ships application-layer products such as Rodeo. TwelveLabs counts customers and traction in media and entertainment and is expanding into government and other verticals including advertising, security, sports, and automotive. It operates R&D in San Francisco and Seoul and plans geographic expansion with new offices in New York and London. The company also maintains a strategic partnership with AWS, including optimization on Trainium chips and prioritized model launches on AWS.

Participated · Seed · Jun 2026

a2sys is developing a software platform aimed at optimising memory utilisation and data movement for AI infrastructure. The company was co-founded by former Samsung and Naver executive Lee Dong-soo and KAIST professor Yu Min-soo and was founded shortly before its seed round. It positions itself as a connector between memory manufacturers (including Samsung and SK Hynix) and AI service providers rather than as a chip maker. The founders argue that AI's evolution toward agentic systems is shifting bottlenecks from GPU computation to memory and data transfer efficiency. a2sys announced a KRW 16 billion (about $11M) seed raise to support development of its platform.

Led · Series B · May 2026

Xpanner’s flagship X1 Kit retrofits customers’ existing construction machines with hardware and software that enable autonomous operation, allowing task-specific automation licenses for piling, material handling, trenching and grading. The company sells automation through an AaaS (Automation-as-a-Service) subscription model while some customers remain on a perpetual modular model that pairs one-time X1 Kit purchases with software. Customers include Mortenson, Black & Veatch, and QCells. Originally founded in South Korea in 2020, Xpanner moved its headquarters to Santa Fe Springs, California in 2023. The company reported revenue growth from $3 million in 2023 to $7 million in 2024 and $21 million in 2025, with $8 million in revenue and $1 million in EBIT in Q1 2026, and it is targeting $60 million in ARR by year-end while maintaining gross margins above 80%. Xpanner achieved monthly break-even in 2025 and is on track for full-year profitability, and it is expanding product development and into adjacent construction verticals.

Led · Series A · Apr 2026

GGWP offers an AI-based moderation and community management platform serving global game publishers across PC, console, and mobile platforms. Its platform supports more than 20 languages and includes in-client game moderation through a partnership with Unity. GGWP entered the Japanese market last year and counts major Asian gaming and technology companies among its strategic investors and partners. The company positions itself as enterprise-grade infrastructure for live service community management, focusing on user protection, retention, and brand safety. Following its $15 million Series A, GGWP is prioritizing expansion in Korea and the Asia-Pacific region and upgrading compliance, stability, and analytics capabilities to support global-scale publishers.

Participated · Equity · Apr 2026

ADEL develops therapeutics targeting central nervous system disorders and advances antibody candidates through clinical development. Its notable programs include ADEL-Y01, a tau antibody candidate that was licensed out to Sanofi in a deal valued up to $1.04 billion with an $80 million non-refundable upfront payment. The company is advancing follow-on candidates ADEL-Y04 (ApoE4-targeting antibody) and ADEL-Y03 (β2-microglobulin-targeting antibody) and aims to accelerate their clinical timelines. ADEL intends to strengthen partnerships with domestic and international CNS specialists and further develop proprietary technology platforms. The company cites global business achievements and investor support as validation of its pipeline value. Management plans to complete a KOSDAQ technology special listing within the year and deploy the newly secured funds to deliver early pipeline development results.